Dasatinib and Thiotepa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dasatinib (dasatinib) and Thiotepa (thiotepa). Common drug interactions include haematotoxicity among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Dasatinib and Thiotepa. It is created by eHealthMe based on reports of 55 people who take the same drugs from the FDA, and is updated regularly.

What is Dasatinib?

Dasatinib has active ingredients of dasatinib. eHealthMe is studying from 9,407 Dasatinib users. Check the latest studies of Dasatinib.

What is Thiotepa?

Thiotepa has active ingredients of thiotepa. eHealthMe is studying from 8,097 Thiotepa users. Check the latest studies of Thiotepa.

On Jul, 28, 2026

55 people who take Dasatinib and Thiotepa together, and have interactions are studied.

Dasatinib and Thiotepa drug interactions.

What are the common drug interactions of Dasatinib and Thiotepa, by gender? *:

female:

Haematotoxicity (toxins that destroy red blood cells)
Drug ineffective
Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
Oedema peripheral (superficial swelling)
Therapeutic response decreased (less preventive response)
Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
Anaemia (lack of blood)
Scleroderma (hard skin)
Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)

male:

Drug ineffective
Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
Device related infection
Gastrointestinal inflammation (inflammation of stomach and intestine)
Lung infection
Parotitis (inflammation of a parotid gland)
Pneumonia
Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
Sepsis (a severe blood infection that can lead to organ failure and death)
Staphylococcal infection (an infection with staphylococcus bacteria)

What are the common drug interactions of Dasatinib and Thiotepa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Drug ineffective
Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
Cystitis haemorrhagic (blood in the urine and painful voiding)
Febrile neutropenia (fever with reduced white blood cells)
Enterococcal bacteraemia (presence of bacteria lactic acid in the blood)
Cytomegalovirus infection
Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
Enterococcal infection
Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
Scleroderma (hard skin)

20-29:

n/a

30-39:

Anaemia (lack of blood)
Intracranial pressure increased (high pressure inside the skull and thus in the brain tissue and cerebrospinal fluid)
Pyrexia (fever)

40-49:

Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
Oedema peripheral (superficial swelling)
Anaemia (lack of blood)
Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
Granulocytopenia (lack of granulocyte)
Thrombocytopenia (decrease of platelets in blood)

50-59:

Haematotoxicity (toxins that destroy red blood cells)
Drug ineffective
Therapeutic response decreased (less preventive response)

60+:

n/a

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 26 people, 47.27%
Bone Marrow Conditioning Regimen: 18 people, 32.73%
B-Cell Type Acute Leukaemia (cancer of the white blood cells): 12 people, 21.82%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 12 people, 21.82%
Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 10 people, 18.18%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 9 people, 16.36%
Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 4 people, 7.27%
Systemic Mycosis (fungal infections of the body): 3 people, 5.45%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 3 people, 5.45%

* Approximation only. Some reports may have incomplete information.

Do you take Dasatinib and Thiotepa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously